To the contrary—Mylan continues its quest for its “second bite” by seeking to preserve its ability to assert invalidity positions in the District Court that Mylan contends are not “specific[ally]” identical to those in the IPR.
Mylan tries to avoid those admissions by repeating the argument that “the litigation timeline is speculative.” As explained in detail in Sanofi’s POPR, that assertion is contrary to the facts and ignores the “unique” and “more urgent” transition date issues in this case.
Mylan’s failure to explain its delay in filing, beyond citing § 315(b), is particularly telling given that Mylan has long had knowledge of the challenged patent based on its listing in the FDA’s Orange Book, as well as the asserted prior art, which was before the Examiner during prosecution.
Inc. v. Iancu, 138 S. Ct. 1348, 1355 (2018), and here Mylan chose its course, preparing and timing its Petition such that it is squarely within the case-specific NHK Spring and General Plastic factors that all weigh strongly in favor of denying institution.
Thus, properly understood, the legislative compromise discussed in Click-to-Call balanced the advantages to petitioners of the limitless filing period for inter partes reexamination under pre-AIA law with the need to provide patent